News | March 11, 2023
Marksans Pharma announces USFDA approval for Famotidine Tablets
Marksans' OTC Famotidine Tablets USP are acid reducers
Marksans' OTC Famotidine Tablets USP are acid reducers
Time to combine innovation, access and technology to deliver positive patient outcomes
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
This artificial RNA ligase has higher thermostability than natural RNA ligase
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product
Subscribe To Our Newsletter & Stay Updated
